Structural basis for the severe adverse interaction of sofosbuvir and amiodarone on L-type Ca_v channels

Prior research has shown that the combination of the hepatitis C antiviral sofosbuvir and the antiarrhythmic agent amiodarone results in life-threatening symptomatic bradycardia. It was already known that amiodarone acts as a non-selective antagonist across multiple cardiac ion channels to manage rhythm disorders. Clinical reports noted that sofosbuvir or its chemical analog MNI-1 significantly enhances the suppression of calcium signaling within cardiomyocytes when amiodarone is present. This synergistic effect specifically targets L-type Voltage-Gated Calcium (Ca_v) channels, which are essential for maintaining the plateau phase of the cardiac action potential. Despite these clinical observations, the precise spatial arrangement and binding kinetics of these molecules within the channel pore remained elusive. The medical community lacked a clear understanding of whether these drugs competed for the same site or functioned through independent mechanisms. This absence of evidence motivated the current investigation into the atomic-scale architecture of the drug-channel complex to prevent future clinical fatalities.

This investigation seeks to elucidate the structural determinants underlying the lethal pharmacodynamic synergy between sofosbuvir and amiodarone. Researchers aimed to determine whether sofosbuvir possesses an intrinsic affinity for the pore-forming subunits of L-type Calcium (Ca_v) channels. The study evaluates how the presence of amiodarone alters the binding landscape for sofosbuvir or its structural derivative MNI-1. Scientists focused on identifying the specific amino acid residues and drug-drug contact points that stabilize the inhibitory complex within the protein scaffold. Mapping the physical obstruction of the ion permeation pathway provides a mechanistic explanation for reduced calcium conductance and subsequent cardiac slowing. The team intended to resolve the specific binding sites for each molecule to understand the cooperative nature of their inhibitory action. Establishing this molecular framework helps clarify why this specific drug combination triggers severe adverse cardiac events in patients undergoing treatment for hepatitis C.

The experimental team employed high-resolution Cryogenic Electron Microscopy (cryo-EM) to visualize the skeletal muscle Ca_v1.1 and cardiac Ca_v1.3 isoforms. Purified channel proteins underwent treatment with amiodarone or sofosbuvir in isolation to define baseline binding characteristics for each individual compound. Subsequent trials necessitated the simultaneous application of amiodarone alongside either sofosbuvir or the analog MNI-1 to capture the ternary complex in a stable state. Data acquisition leveraged advanced electron detection systems to resolve the density maps of the transmembrane pore domains at near-atomic resolution. Computational modeling and structural refinement permitted the precise placement of drug molecules within the observed electron densities of the channel subunits. Systematic comparison of the apo-state and drug-bound structures displayed conformational changes induced by the ligands within the pore and voltage-sensing domains. The researchers applied these structural maps to ascertain the proximity between the drugs and the surrounding amino acid side chains within the pore.

Structural data demonstrated that amiodarone independently occupies the classical dihydropyridine binding pocket located within the channel's voltage-sensing domain. Sofosbuvir failed to show any detectable binding or density within the Ca_v channel architecture when administered without the presence of amiodarone. The presence of amiodarone creates a unique docking site that enables sofosbuvir or MNI-1 to anchor firmly within the central cavity of the pore. This ternary arrangement comprises direct physical interactions between the two drug molecules, effectively wedging the antiviral into the ion conduction pathway. The resulting molecular assembly physically occludes the ion conduction path, preventing the movement of calcium ions through the membrane during depolarization. These findings confirm that amiodarone acts as a necessary scaffold for sofosbuvir-mediated channel blockade, explaining the observed clinical toxicity. The study concluded that the interaction is highly specific to the chemical structure of these two therapeutic agents and their spatial orientation within the protein scaffold.

The study establishes a definitive structural model for the dangerous pharmacodynamic interaction between these two distinct therapeutic classes. These results clarify the molecular etiology of fatal heartbeat slowing observed in patients receiving concurrent hepatitis C and arrhythmia treatments. Recognizing the central cavity as the site of drug-drug stabilization offers a new perspective on multi-drug toxicity mechanisms in cardiac tissue. Future pharmacological screening for antiviral candidates should consider potential scaffold-mediated interactions with existing cardiac medications to avert similar adverse events. This structural insight provides a basis for designing safer nucleotide analogs that lack the specific moieties required for amiodarone-dependent binding. The research highlights the necessity of structural biology in predicting and preventing severe adverse drug reactions in clinical settings. By understanding the physical basis of this interaction, clinicians can better manage the risks associated with polypharmacy in complex patient populations and improve overall patient safety.